Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 8:11:616629.
doi: 10.3389/fonc.2021.616629. eCollection 2021.

Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges

Alhadi Almangush  1   2   3   4   5 , Ilmo Leivo  4   6 , Antti A Mäkitie  2   7   8
Affiliations
Review

Biomarkers for Immunotherapy of Oral Squamous Cell Carcinoma: Current Status and Challenges

Alhadi Almangush et al. Front Oncol. .

Abstract

Oral squamous cell carcinoma (OSCC) forms a major health problem in many countries. For several decades the management of OSCC consisted of surgery with or without radiotherapy or chemoradiotherapy. Aiming to increase survival rate, recent research has underlined the significance of harnessing the immune response in treatment of many cancers. The promising finding of checkpoint inhibitors as a weapon for targeting metastatic melanoma was a key event in the development of immunotherapy. Furthermore, clinical trials have recently proven inhibitor of PD-1 for treatment of recurrent/metastatic head and neck cancer. However, some challenges (including patient selection) are presented in the era of immunotherapy. In this mini-review we discuss the emergence of immunotherapy for OSCC and the recently introduced biomarkers of this therapeutic strategy. Immune biomarkers and their prognostic perspectives for selecting patients who may benefit from immunotherapy are addressed. In addition, possible use of such biomarkers to assess the response to this new treatment modality of OSCC will also be discussed.

Keywords: biomarkers; immune response; immunotherapy; oral squamous cell carcinoma; survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Almangush A, Heikkinen I, Makitie AA, Coletta RD, Laara E, Leivo I, et al. Prognostic biomarkers for oral tongue squamous cell carcinoma: a systematic review and meta-analysis. Br J Cancer (2017) 117:856–66. 10.1038/bjc.2017.244 - DOI - PMC - PubMed
    1. Rivera C, Oliveira AK, Costa RAP, De Rossi T, Paes Leme AF. Prognostic biomarkers in oral squamous cell carcinoma: A systematic review. Oral Oncol (2017) 72:38–47. 10.1016/j.oraloncology.2017.07.003 - DOI - PubMed
    1. Adams JL, Smothers J, Srinivasan R, Hoos A. Big opportunities for small molecules in immuno-oncology. Nat Rev Drug Discovery (2015) 14:603–22. 10.1038/nrd4596 - DOI - PubMed
    1. Huang PW, Chang JW. Immune checkpoint inhibitors win the 2018 Nobel Prize. BioMed J (2019) 42:299–306. 10.1016/j.bj.2019.09.002 - DOI - PMC - PubMed
    1. Zandberg DP, Algazi AP, Jimeno A, Good JS, Fayette J, Bouganim N, et al. Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with >/=25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy. Eur J Cancer (2019) 107:142–52. 10.1016/j.ejca.2018.11.015 - DOI - PubMed

LinkOut - more resources